Doctors looking for children with chronic migraines for new study 14news.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from 14news.com Daily Mail and Mail on Sunday newspapers.
VANCOUVER, BC, June 15, 2022 /PRNewswire/ BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or "Company"), announced today that its clinical study collaborator Hospices
Chesapeake Financial Shares Inc, the parent company of Chesapeake Bank, announced in its second-quarter shareholder letter that EVP of Retail Services.
VANCOUVER, BC, June 15, 2022 /PRNewswire/ BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or "Company"), announced today that its clinical study collaborator Hospices Civils de Lyon in France ("HCL") has surgically excised the first ovarian cancer tumors from cancer patients to be used by BioVaxys for process development and manufacturing "dry runs" of BVX-0918, a major step leading to the completion of Good Manufacturing Process ("GMP") production of the Company's ovarian cancer vaccine. BioVaxys recently entered collaborations with HCL and Deaconess Research Institute in the United States to provide the Company with surgically debulked tumors from Stage III/Stage IV ovarian cancer patients. Tumor samples from both hospitals are being used by BioVaxys' Lyon-based manufacturing partner, BioElpida ("BioElpida"), to validate the tumor collection protocol, cryopackaging, cryopreservation, and
Chesapeake Financial Shares Inc, the parent company of Chesapeake Bank, announced in its second-quarter shareholder letter that EVP of Retail Services.